Translate Bio (Translate Bio) Net Margin % : 23.60% (As of Jun. 2021)

View and export this data going back to 2018. Start your Free Trial

What is Translate Bio Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Translate Bio's Net Income for the three months ended in Jun. 2021 was $17.1 Mil. Translate Bio's Revenue for the three months ended in Jun. 2021 was $72.6 Mil. Therefore, Translate Bio's net margin for the quarter that ended in Jun. 2021 was 23.60%.

The historical rank and industry rank for Translate Bio's Net Margin % or its related term are showing as below:

TBIO' s Net Margin % Range Over the Past 10 Years
Min: -6858.8 Med: -1451.73 Max: 17.97
Current: 17.97

TBIO's Net Margin % is not ranked
in the Biotechnology industry.
Industry Median: -160.92 vs TBIO: 17.97

Translate Bio Net Margin % Historical Data

The historical data trend for Translate Bio's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Translate Bio Net Margin % Chart

Translate Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Net Margin %

-6,858.80

-1,451.73

-38.75

Translate Bio Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Net Margin %	Get a 7-Day Free Trial														-222.37	26.10	-40.01	76.65	23.60

Competitive Comparison of Translate Bio's Net Margin %

For the Biotechnology subindustry, Translate Bio's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Translate Bio's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Translate Bio's Net Margin % distribution charts can be found below:

* The bar in red indicates where Translate Bio's Net Margin % falls into.

Translate Bio Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Translate Bio's Net Margin for the fiscal year that ended in Dec. 2020 is calculated as

Net Margin	=	Net Income (A: Dec. 2020 )	/	Revenue (A: Dec. 2020 )
	=	-53.787	/	138.811
	=	-38.75 %

Translate Bio's Net Margin for the quarter that ended in Jun. 2021 is calculated as

Net Margin	=	Net Income (Q: Jun. 2021 )	/	Revenue (Q: Jun. 2021 )
	=	17.144	/	72.649
	=	23.60 %

Translate Bio (NAS:TBIO) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Translate Bio Net Margin % Related Terms

Thank you for viewing the detailed overview of Translate Bio's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Translate Bio (Translate Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Translate Bio Inc (NAS:TBIO) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Hartwell Avenue, Lexington, MA, USA, 02421

Website

http://www.translate.bio

Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.

Executives

Jean Francois Formela	director	C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Renaud Ronald C Jr	director, officer: Chief Executive Officer, other: President	C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02109
Paul D. Burgess	officer: Chief Operating Officer, CLO, other: Secretary	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Owen Hughes	director	C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Shire Human Genetic Therapies, Inc.	10 percent owner	300 SHIRE WAY LEXINGTON MA 02421
Takeda Pharmaceutical Co Ltd	10 percent owner	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Baupost Group Gp, L.l.c.	10 percent owner	10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116
Seth A Klarman	10 percent owner	10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Baupost Group Llc/ma	10 percent owner	10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116
George Demetri	director	BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Daniella Beckman	director	C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
Robert M Plenge	director	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Daniel Lynch	director
Robert J. Meyer	director	2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713
Ann Barbier	officer: Chief Medical Officer	255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109